- Home
- IGC vs PULM Comparison
IGC vs PULM Comparison
Compare IGC & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- PULM
- Stock Information
- Founded
- IGC 2005
- PULM 2003
- Country
- IGC United States
- PULM United States
- Employees
- IGC N/A
- PULM N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- IGC Health Care
- PULM Health Care
- Exchange
- IGC Nasdaq
- PULM Nasdaq
- Market Cap
- IGC 33.5M
- PULM 33.2M
- IPO Year
- IGC N/A
- PULM N/A
- Fundamental
- Price
- IGC $0.37
- PULM $5.62
- Analyst Decision
- IGC Strong Buy
- PULM
- Analyst Count
- IGC 2
- PULM 0
- Target Price
- IGC $3.88
- PULM N/A
- AVG Volume (30 Days)
- IGC 7.5M
- PULM 11.2K
- Earning Date
- IGC 08-07-2025
- PULM 08-12-2025
- Dividend Yield
- IGC N/A
- PULM N/A
- EPS Growth
- IGC N/A
- PULM N/A
- EPS
- IGC N/A
- PULM N/A
- Revenue
- IGC $1,271,000.00
- PULM $1,921,000.00
- Revenue This Year
- IGC $15.26
- PULM N/A
- Revenue Next Year
- IGC $3.41
- PULM $134.88
- P/E Ratio
- IGC N/A
- PULM N/A
- Revenue Growth
- IGC N/A
- PULM N/A
- 52 Week Low
- IGC $0.25
- PULM $1.78
- 52 Week High
- IGC $0.48
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- IGC 54.60
- PULM 32.49
- Support Level
- IGC $0.30
- PULM $5.60
- Resistance Level
- IGC $0.46
- PULM $6.15
- Average True Range (ATR)
- IGC 0.04
- PULM 0.28
- MACD
- IGC 0.00
- PULM -0.05
- Stochastic Oscillator
- IGC 33.00
- PULM 1.63
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).